Pharma Focus Asia

Merck Invests US$29 million (€28 million) to Open Drug Manufacturing Sites in Germany


Merck plans to invest US$29 million (€28 million) to open two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.


The new manufacturing facilities will offer a comprehensive solution for every critical facet of mRNA development, production, and market deployment, encompassing not only the creation of mRNA products but also their rigorous testing.

This encompasses specialised analytical development and biosafety testing explicitly tailored for mRNA technologies, ensuring the highest quality and safety standards are met.

These state-of-the-art facilities play a crucial role in an ongoing investment programme designed at advancing mRNA technologies. In addition, this will also generate 75 new employment opportunities. This integrated approach simplifies processes and reduces complexities.


Name   Merck
Type   New Facility
Budget US$29 million (€28 million)

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024